Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.60 |
| ▸ | HPGD | P15428 | 6/20 | 0.60 |
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | GLA | P06280 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.55 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3377076 | 0.87 | RAB9A (0.68) | ALDH1A1SMN1; SMN2KDM4EHPGDNPC1 | |
| SCHEMBL38656864 | 0.82 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2KDM4EHPGDNPC1 | |
| SCHEMBL2345607 | 0.81 | CYP19A1 (0.74) | ALDH1A1SMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL4880206 | 0.80 | KDM4E (0.89) | ALDH1A1SMN1; SMN2KDM4EHPGDNPC1 | |
| SCHEMBL4880945 | 0.80 | NPC1 (0.59) | ALDH1A1SMN1; SMN2KDM4EHPGDNPC1 | |
| SCHEMBL26915290 | 0.79 | SMN1; SMN2 (0.58) | ALDH1A1SMN1; SMN2KDM4EHPGDNPC1 | |
| SCHEMBL26915340 | 0.79 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2KDM4EHPGDNPC1 | |
| SCHEMBL29215197 | 0.78 | NPC1 (0.57) | ALDH1A1SMN1; SMN2KDM4EHPGDNPC1 | |
| SCHEMBL4882549 | 0.78 | RAB9A (0.87) | ALDH1A1SMN1; SMN2KDM4EHPGDNPC1 | |
| SCHEMBL29248979 | 0.77 | ALOX15 (0.56) | ALDH1A1SMN1; SMN2KDM4EHPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2008-01-17 | — | — | US | claimed |
| WO-2007149395-A2 | 2,5-SUBSTITUTED OXAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | AMPHORA DISCOVERY CORPORATION (US) | 2007-12-27 | — | — | WO | claimed |
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2008-01-17 | — | — | US | disclosed |
| WO-2007149395-A2 | 2,5-SUBSTITUTED OXAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | AMPHORA DISCOVERY CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | ATP5ME, ATP5MG, ATP5MK | ALDH1A1 404/4885SMN1; SMN2 4756/4885KDM4E 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.